In response to public outrage over the EpiPen price hike, pharmaceutical company Mylan said it will introduce an identical generic version with a wholesale list price of $300 for a pack of two, instead of more than $600 for the…
Supply Chain
Former Turing Pharmaceutical CEO Martin Shkreli said via Twitter that insurers should cover some of the cost to make the drug more affordable, according to USA Today.
A bipartisan group of senators on Wednesday sent a letter to Food and Drug Administration Commissioner Robert Califf, MD, urging the agency to help bring more EpiPen competitors to the market.
After Mylan CEO Heather Bresch blamed the pharmaceutical "middlemen" for causing the high price of EpiPens in an interview Thursday, Steve Miller, MD, CMO of Express Scripts, countered that her statement couldn't be "farther from the truth," reported CNBC.
Heather Bresch, the Mylan CEO at the center of the EpiPen pricing controversy, addressed scrutiny over the Canonsburg, Pa.-based company's pricing practices in a televised interview Thursday on CNBC.
Advertisement
Sen. Joe Manchin (D-W.Va.) issued a statement Thursday regarding the high cost of EpiPens, reported ABC News. His daughter, Heather Bresch, is CEO of Mylan, the company behind the epinephrine injection.
Here are the five latest medical devices or drugs approved by the Food and Drug Administration.
Mylan is not the only drug company reaping financial benefits from excessive price hikes, reports USA Today.
The Food and Drug Administration recently approved a new post-dermal procedure product developed by Oculus Innovative Sciences.
The Food and Drug Administration rejected Amgen's new drug intended to treat hormonal imbalances that commonly occur in patients on dialysis, reports The Wall Street Journal.